Sign In
Buy BEAM
$25.52
-0.97 (-3.66%)
At Close: Jul 31, 2026
Beam Therapeutics Announces Acquisition of Guide Therapeutics
08:34am, Tuesday, 23'rd Feb 2021
GuideTx's Proprietary LNP Screening Technology and Lipid Library Supports Expanded Targeting of Diverse Tissues for In Vivo Delivery of Gene Editing GuideTx's Proprietary LNP Screening Technology and
Beam, SpringWorks Biggest Gainers on BioSpace List
06:14pm, Tuesday, 19'th Jan 2021
Among the public companies that made the BioSpace list of the top up and coming life sciences firms in 2019 and 2020, the majority have seen gains in their share prices. Given this metric, investors m
Beam Therapeutics Inc. Announces $260 Million Common Stock Investment from Multiple Investors
06:30am, Tuesday, 19'th Jan 2021
CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM) (the “Company”), a biotechnology company developing precision genetic medicines through base editing, toda
7 CRISPR Stocks for the Future of Medicine
06:12pm, Friday, 15'th Jan 2021
Between these seven genetic editing pioneers, you have the widest exposure to the biggest scientific breakthrough of the century. The post 7 CRISPR Stocks for the Future of Medicine appeared first on
Beam Therapeutics Appoints Leading Healthcare Executive Kate Walsh to its Board of Directors
06:30am, Monday, 11'th Jan 2021
CAMBRIDGE, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Kat
Implied Volatility Surging for Beam Therapeutics (BEAM) Stock Options
09:47am, Wednesday, 06'th Jan 2021
Investors need to pay close attention to Beam Therapeutics (BEAM) stock based on the movements in the options market lately.
Beam Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
06:30am, Tuesday, 05'th Jan 2021
CAMBRIDGE, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Joh
Top ETF of December & Its Best Stocks
12:03pm, Thursday, 24'th Dec 2020
We have highlighted the best ETF of December and its best performing stocks.
MoneyLine Podcast: These Stocks are Making MASSIVE Moves
04:13pm, Tuesday, 08'th Dec 2020
Listen in to hear how you can profit in 2021 and beyond
Beam Therapeutics: Early Stage Gene Editing Company With Cutting Edge Technology
10:00am, Saturday, 05'th Dec 2020
Beam Therapeutics was co-founded by David Liu, who invented base editing and prime editing technologies for gene editing. David Liu also co-founded Editas.
Beam Therapeutics Presents Updated Data from Novel Base Editing Programs for Sickle Cell Disease at ASH 2020
07:00am, Saturday, 05'th Dec 2020
BEAM-101 Data Highlight Precision of Base Editor with No Off-Target Editing Observed ; Will Support Planned IND Submi ssion in the Second Half of 2021
The Boston Globe Names Beam Therapeutics a Top Place to Work for 2020
04:01pm, Friday, 20'th Nov 2020
Magazine honors company for second year in a row Magazine honors company for second year in a row
Beam Therapeutics Presents First Data Highlighting Base Editing Program for Glycogen Storage Disease Type Ia at AASLD
08:00am, Friday, 13'th Nov 2020
Novel Base Edit ors for Two Most Common GSDIa Mutations Demonstrate Significantly Higher Levels of In Vivo Mutation C orrection than Required to Restore Glucose H omeostasis
Beam Therapeutics Announces Business and Pipeline Progress and Reports Third Quarter 2020 Financial Results
06:30am, Tuesday, 10'th Nov 2020
BEAM -201 , a n Off the Shelf Allogeneic CD7-Targeting CAR-T , Named as Development Candidate for Treatment of T-ALL ; First Cell Therapy Featuring Four Simultaneous Genetic Edits ; Demonstrates 96-99
BEAM-201, an Off the Shelf Allogeneic CD7-Targeting CAR-T, Named as Development Ca ndidate for Treatment of T- Cell Acute Lymphoblastic Leukemia
